Feature | GP5 | GP12 |
---|---|---|
Prostate and urinary history in years prior to PrCa diagnostic biopsy | Age 55.8 symptoms of BPH and PSA 1.8, started on dutasteride. PSA dropped to 0.7 on dutasteride age 58.6, when dutasteride stopped. PSA then steadily rose from 2.8 at age 61, to 12 (percent free 13%) at age 63.6 despite the course of finasteride, just before PrCa diagnostic biopsy | Age 56.2 PSA 2.3 (26% free), Age 58.5 PSA 10 (19% free) led to prostate biopsy |
Urinary symptoms just prior to PrCa diagnostic biopsy | Urinary urgency and nocturia | Urinary frequency and decreased urinary stream |
Plasma PSA just prior to PrCa diagnostic biopsy | 12Â ng/mL | 10Â ng/mL |
Family history of cancer in first-degree relatives | History of lethal cancer in father and mother | History of cancer in father |
Race/ancestry | White/Finnish | White/Finnish |
AJCC 7th edition clinical stage ( in use at study entry) | T2b NxM0 | T2c NxM0 |
Biopsy Gleason Grade Group | 5 | 5 |
Pathologic stage (after RP) | pT3aN1M0, stage group IVA | pT3bN1M0, stage group IVA |
Radical prostatectomy Gleason Grade Group | 5 | 5 |
Age at PrCa Diagnostic Biopsy/RP | 63.6/63.8Â years | 58.5/58.7Â years |
Postoperative status (patient follow-up period: up to 6 years after RP) | Received EBRT to prostate fossa in the postoperative period. Put on leuprolide and bicalutamide. PSA nadir post RP 0.3 ng/mL. PSA 6 years postop 0.11 ng/mL. Status M0 at 6 years postop | Received EBRT to prostate fossa and pelvic lymph nodes in the postoperative period. Bone metastasis found 2 years post RP. PSA nadir post-RP 0.9 ng/mL, > 1000 ng/mL at 6 years postop after bicalutamide, orchiectomy, cabazitaxel, carboplatin, and radium 223 treatments, shifted to palliative care with status M1c |